Smith & Nephew SNATS Inc
$ 32.84
-4.00%
21 Apr - close price
- Market Cap 14,015,649,000 USD
- Current Price $ 32.84
- High / Low $ 33.77 / 32.68
- Stock P/E 22.96
- Book Value 2.49
- EPS 1.43
- Next Earning Report 2026-05-06
- Dividend Per Share $0.39
- Dividend Yield 2.38 %
- Next Dividend Date 2026-05-27
- ROA 0.05 %
- ROE 0.12 %
- 52 Week High 37.90
- 52 Week Low 25.72
About
Smith & Nephew plc develops, manufactures, markets and sells medical devices worldwide. The company is headquartered in Watford, the United Kingdom.
Analyst Target Price
$36.62
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-24 | 2025-11-06 | 2025-08-05 | 2025-04-30 | 2025-02-25 | 2024-10-31 | 2024-08-01 | 2024-05-01 | 2024-02-27 | 2023-11-02 | 2023-08-03 | 2023-04-26 |
| Reported EPS | 0.38 | 0 | 0.33 | 0 | 0.23 | 0 | 0.756 | 0 | 1.31 | 0 | 0.35 | 0 |
| Estimated EPS | 1.12 | 0 | 1.03 | 0 | 0.97 | 0 | 0.93 | 0 | 0.96 | 0 | 0.81 | 0 |
| Surprise | -0.74 | 0 | -0.7 | 0 | -0.74 | 0 | -0.174 | 0 | 0.35 | 0 | -0.46 | 0 |
| Surprise Percentage | -66.0714% | None% | -67.9612% | None% | -76.2887% | None% | -18.7097% | None% | 36.4583% | None% | -56.7901% | None% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-06 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 0 |
| Currency | USD |
Previous Dividend Records
| May 2026 | Nov 2025 | May 2025 | Nov 2024 | May 2024 | Nov 2023 | May 2023 | Oct 2022 | May 2022 | Jan 1970 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-05-27 | 2025-11-07 | 2025-05-28 | 2024-11-08 | 2024-05-22 | 2023-11-01 | 2023-05-17 | 2022-10-26 | 2022-05-11 | None |
| Amount | $0.482 | $0.3 | $0.462 | $0.288 | $0.462 | $0.288 | $0.462 | $0.288 | $0.462 | $0.288 |
Next Dividend Records
| Dividend per share (year): | $0.39 |
| Dividend Yield | 2.38% |
| Next Dividend Date | 2026-05-27 |
| Ex-Dividend Date | 2026-03-27 |
Recent News: SNN
2026-04-21 12:09:34
Smith+Nephew announced compelling new 5-year data from a randomized controlled trial for its CARTIHEAL AGILI-C Cartilage Repair Implant, published in the American Journal of Sports Medicine. The data showcases superior pain relief and functional gains, with patients reporting significantly better outcomes than standard care. The implant is especially beneficial for patients with and without osteoarthritis, offering a durable solution for those in the "osteoarthritis treatment gap."
2026-04-21 12:01:53
Smith+Nephew announced compelling 5-year results for its CARTIHEAL AGILI-C Cartilage Repair Implant, showing superior pain relief and functional gains compared to the surgical standard of care. The implant delivered twice the reduction in pain scores and comparable clinical outcomes for both osteoarthritis and non-osteoarthritis patients. This FDA-approved device, made of aragonite, offers a durable solution for patients in the treatment gap between cartilage repair and joint replacement, and will receive a Category I CPT code in 2027.
2026-04-21 12:01:53
Smith+Nephew announced new 5-year data for its CARTIHEALâ—Š AGILI-Câ—Š Cartilage Repair Implant, demonstrating superior pain relief and functional gains compared to standard care. The FDA-approved implant showed higher KOOS scores and twice the pain reduction over 60 months, with comparable results for patients with and without osteoarthritis. The implant also received a Category I CPT code, effective January 1, 2027, which will aid in reimbursement for procedures.
2026-04-19 11:39:32
Google's 2026 Discover Core Update is significantly changing how financial news, especially for mobile-first investors, is consumed. For companies like Smith & Nephew plc (ADR), this shift prioritizes visual, engaging, and topically authoritative content, potentially boosting their orthopedic and sports medicine stories among retail investors. The article emphasizes how Smith & Nephew's product-rich portfolio lends itself well to Discover's visual demands, offering a new avenue for retail sentiment and trading.
2026-04-18 15:08:50
Google's 2026 Discover Core Update is revolutionizing how financial news, particularly for companies like Smith & Nephew, reaches investors by prioritizing personalized, visually rich content. This shift is crucial for medtech visibility, as Smith & Nephew's innovative orthopedic and sports medicine products lend themselves well to the visual content Discover favors, potentially influencing retail sentiment and trading of SNN shares. The update emphasizes images, topical authority, and local relevance, providing a new way for investors to track company narratives before traditional reports emerge.
2026-04-18 07:39:58
Smith & Nephew plc (ADR) offers investors exposure to high-growth medtech segments like orthopedics, sports medicine, and wound care through its NYSE-listed American Depositary Receipts (SNN). The article highlights the company's competitive strengths, including innovative technologies in hip and knee replacements, advanced wound management, and a strong balance sheet. It suggests potential undervaluation compared to peers, a solid dividend yield, and significant long-term growth driven by aging demographics and increasing demand for medical interventions.
